Braftovi (encorafenib) combination regimen significantly improved progression-free survival and overall survival in Phase III BREAKWATER trial – Pfizer
Pfizer Inc. announced positive topline results from the progression-free survival (PFS) analysis of the Phase III BREAKWATER study of Braftovi (encorafenib) in combination with cetuximab (Erbitux) and mFOLFOX6… read more.
